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Preoperative High Neutrophil-Lymphocyte Ratio 
May Be Associated with Lateral Lymph Node 
Metastasis in Patients with Papillary Thyroid 
Cancers
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Background and Objectives: The present study investigated the association between preoperative neutrophil- 
to-lymphocyte ratio (NLR) and poor prognostic outcomes in conventional papillary thyroid carcinomas (cPTCs). 
Materials and Methods: Two hundred and five patients who underwent total thyroidectomy for cPTCs larger 
than 10 mm were evaluated retrospectively. Patients were classified into the low NLR (n=103) and high NLR 
(n=102) groups by the median NLR value (1.78) and logistic regression analysis was used to evaluate whether 
the NLR predicted aggressive PTC features. Patients were also classified into the disease-free (n=183) and 
persistence/recurrence (n=22) groups and Cox regression analysis was used to investigate factors affecting 
persistence/recurrence by Cox regression analysis. Results: The high NLR group had a higher presence of lateral 
lymph node metastasis (p=0.004) and higher radioactive iodine doses (p=0.006) than the low NLR group. High 
NLR was an independent predictor of lateral lymph node metastasis (LNM) (OR, 2.786; p=0.005) but was not 
significantly associated with persistence/recurrence. Conclusion: Preoperative high NLR was an independent 
predictor of lateral LNM in cPTCs.
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Introduction
Thyroid carcinoma accounts for roughly 1% of all 
new malignant diseases and has increased in in-
cidence due to the use of ultrasonography (US).1) At 
least 94% of thyroid carcinomas are differentiated thy-
roid carcinomas, with papillary thyroid carcinoma 
(PTC) being the most common subtype.1) Fortunately, 
PTC exhibits indolent, localized features and generally 
shows good prognosis. Ten-year overall survival 
rates for PTC are reported to be 93-98%.2,3) Despite 
relatively good prognosis, 10-year recurrence rates 
for PTCs are quite high with values reported to be 
14-26%.2,3) Established unfavorable prognostic factors 
of PTC are age at diagnosis, tumor size, extrathyroidal 
extension, lymph node metastasis, histologic subtype 
(tall cell, columnar cell, diffuse sclerosing, and insular 
variants), incomplete surgery, and omitted or in-
sufficient radioactive iodine therapy.4,5) In recent years, 
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there has been wider acceptance about the critical 
role systemic inflammation plays in the evolution of 
cancer.6-8) In the physiologic inflammatory process, 
wound healing is self-limited by balancing anti- and 
pro-inflammatory factors. However, cancers are 
“wounds that do not heal” by persistent and dysregu-
lated inflammatory factors.9) Neutrophils, the first re-
cruited cells in an acute inflammation, are major sour-
ces of cytokines/chemokines necessary for in-
flammatory cell recruitment, activation and reaction.7) 
Recent studies have suggested that pre-treatment in-
flammatory parameters based on blood tests (such as 
the C-reactive protein, albumin, neutrophil and platelet 
counts) can be predictors of cancer prognosis.10) 
Among these inflammatory parameters, the pretreat-
ment high neutrophil-to-lymphocyte ratio (NLR) has 
been especially associated with adverse outcomes in 
various cancer entities.11) In patients with thyroid can-
cers, a higher NLR has been associated with larger 
tumor size,12,13) high stage,14) old age,13,14) and poorer 
differentiated cancer.15) Therefore, we investigated 
whether preoperative NLR is associated with poor 
prognostic outcomes in conventional PTCs (cPTCs) 
which comprises the majority of thyroid malignancies. 
Materials and Methods
The Institutional Review Board of our institution ap-
proved this retrospective study. Neither patient appro-
val nor informed consent for review of patient medical 
records was required. 
Patients
From January 2005 to February 2006, 248 patients 
who underwent total thyroidectomy for cPTC larger 
than 10 mm and were followed up for more than 3 
years at our institution (a referral center) were initially 
considered as candidates for our study. After exclud-
ing 43 patients without available preoperative blood 
cell counts (neutrophils and lymphocytes) within a 
week before surgery, 205 patients were finally in-
cluded in this study. The NLR was calculated as the 
absolute neutrophil count divided by the absolute lym-
phocyte count. The mean follow-up period after sur-
gery was 93.6 months (median, 108.4 months; range, 
36-125.4 months). All patients in this study had been 
included in the study population of a previously pub-
lished article.16) However, the previous study had dif-
ferent research purposes from our own and did not 
deal with the same concepts.
Surgery and Pathologic Diagnosis
In our institution, patients with multifocal or bilateral 
lesions, extrathyroidal extension, or lymph node meta-
stasis underwent total thyroidectomy. Prophylactic 
central node dissection was routinely performed on all 
patients, and lateral neck dissection including levels 2, 
3, 4 and anterior 5, was selectively performed on pa-
tients with preoperatively or intraoperatively suspicious 
lymph nodes. US-guided fine-needle aspiration or in-
traoperative frozen biopsy was performed to diagnose 
metastatic lymph nodes, respectively. Tumor size, ex-
trathyroidal extension, multifocality, and lymph node 
metastasis were determined from the final pathologic 
records. Pathologic tumor-node metastasis (TNM) 
staging was classified according to the eighth edition 
of the American Joint Committee on Cancer.17) 
Follow-up Investigation and Persistence/Recurrence
All patients received thyroid stimulating hormone 
(TSH) suppressive therapy with levothyroxine after 
surgery. Radioactive iodine treatment was given to 
patients with histopathology-proven extrathyroidal ex-
tension or lymph node metastasis. Patients who un-
derwent surgery were followed up at 6-month inter-
vals for the first 3 years and annually thereafter. 
Follow-up investigations included a clinical examina-
tion every 6 months; laboratory tests including free 
T4, TSH, non-stimulated or stimulated thyroglobulin, 
thyroglobulin antibody (Ab); a chest X-ray; and a 
neck US examination every 12 months. Iodine-131 
whole-body scan or fluorodeoxyglucose positron 
emission tomography (PET)/computed tomography 
(CT) were performed in specific cases, such as cases 
with detectable or persistent serum Tg or anti-Tg anti-
body without radiological evidence of recurrence. 
Clinical endpoints were divided into three categories: 
no clinical evidence of disease (NED), persistence, 
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Table 1. Patient characteristics
Characteristics All patients (n=205) High NLR* (n=102) Low NLR† (n=103) p 
Age 47±13.04 46.82±13.48 47.18±12.66 0.848
Gender 0.016
  Female 175 (85.4) 81 (79.4) 94 (91.3)
  Male 30 (14.6) 21 (20.6) 9 (8.7)
Mean size (mm) 18.88±8.42 19.61±8.96 18.17±7.83 0.221
Multifocality 66 (32.2) 34 (33.3) 32 (31.1) 0.729
ETE 0.883
  Intrathyroid 54 (26.3) 26 (25.5) 28 (27.2)
  Minimal ETE 134 (65.4) 68 (66.7) 66 (64.1)
  Strap muscle invasion 12 (5.9) 5 (4.9) 7 (6.8)
  Major organ invasion 5 (2.4) 3 (2.9) 2 (1.9)
Central LNM 115 (56.1) 55 (53.9) 60 (58.3) 0.532
Lateral LNM 47 (22.9) 32 (31.4) 15 (14.6) 0.004
RAI dose 35.10±38.90 42.60±51.96 27.67±15.54 0.006
TNM stage 0.941
  I 172 (83.9) 85 (83.3) 87 (84.5)
  II 30 (14.6) 15 (14.7) 15 (14.6)
  III 0 0 0
  IV 3 (1.5) 2 (2.0) 1 (1.0)
Distant metastasis 5 (2.4) 4 (3.9) 1 (1.0) 0.212
Persistence/recurrence 22 (10.7) 14 (13.7) 8 (7.8) 0.168




and recurrence. NED was defined with suppressed 
serum Tg＜1 ng/mL, no detectable TgAb, and no 
structural evidence of disease. Structural evidence of 
disease was defined as i) biopsy-proven disease 
(cytologially or histologically), or ii) highly suspicious 
finding of lymph nodes or operative bed nodules at 
neck US examination, or iii) highly suspicious for 
metastatic disease on cross-sectional imaging modal-
ity (US, CT, or magnetic resonance imaging) or func-
tional imaging (radioactive iodine [RAI] scan or 
PET/CT). Persistence was defined as biochemical 
(suppressed serum Tg≥1 ng/mL and/or stimulated 
Tg≥2 ng/mL) or structural evidence of disease that 
existed after surgery or RAI ablation. Newly detected 
biochemical, structural, or functional evidence of dis-
ease during any period of NED was defined as 
recurrence.18) The clinical endpoint was persis-
tence/recurrence first detected after initial treatment 
(including surgical resection and first RAI treatment if 
performed). 
Statistical Analysis
The methods of Contal and O’Quigley were used 
to determine the optimal cut-off point of NLR with the 
log-rank test (with log-rank statistics). When the opti-
mal cut-off point which maximized the hazard ratio of 
disease-free survival was applied, there was no stat-
istical significant difference between the high NLR and 
low NLR groups (NLR=2.29, p=0.190). Because our 
data did not show normal distribution by the 
Kolmogorov-Smirnov test (p＜0.01), we used the me-
dian NLR value (1.78; mean, 2.237; range, 0.677- 
14.689) as the reference value. Patients were divided 
into either the high NLR group or the low NLR group 
according to the median NLR for statistical analysis. 
We used the independent two-sample t-test or 
chi-square test to compare the clinicopathologic dif-
ferences between the high NLR and low NLR groups. 
The univariate and multivariate logistic regression 
analyses were used to evaluate which NLR predicted 
aggressive PTC features (extrathyroidal extension, 
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Table 2. Predictors of extrathyroidal extension and central/lateral neck lymph node metastasis defined by univariate and 
multivariate logistic regression analyses 
Variables
Univariate Multivariate
OR (95% CI) p OR (95% CI) p
ETE
  Age 1.034 (0.995, 1.075) 0.084 1.031 (0.994,1.071) 0.104
  Gender 0.000 (0.000) 0.998 0.000 (0.000) 0.998
  Mean size 1.018 (0.964, 1.075) 0.528 1.010 (0.951, 1.072) 0.730
  Multifocality 0.867 (0.293, 2.572) 0.798 0.821 (0.268, 2.514) 0.730
  LNM 1.817 (0.615, 5.363) 0.280 1.683 (0.5541, 5.236) 0.368
  High NLR* 0.889 (0.329, 2.403) 0.816 1.085 (0.392, 3.003) 0.876
Central LNM
  Age 0.991 (0.971, 1.013) 0.424 0.987 (0.966, 1.009) 0.254
  Gender 0.75 (0.345, 1.629) 0.467 0.767 (0.341, 1.727) 0.522
  Mean size 1.039 (1.003, 1.077) 0.035 1.042 (1.005, 1.081) 0.025
  Multifocality 0.998 (0.553, 1.801) 0.994 0.970 (0.529, 1.779) 0.922
  ETE 1.981 (0.671, 5.844) 0.216 1.927 (0.637, 5.822) 0.245
  High NLR* 0.839 (0.483, 1.457) 0.532 0.815 (0.460, 1.446) 0.485
Lateral LNM
  Age 1.013 (0.988, 1.039) 0.302 1.010 (0.984, 1.036) 0.454
  Gender 0.817 (0.313, 2.135) 0.680 0.593 (0.210, 1.675) 0.324
  Mean size 1.046 (1.009, 1.085) 0.014 1.041 (1.002, 1.081) 0.037
  Multifocality 1.804 (0.921, 3.534) 0.086 1.685 (0.833, 3.412) 0.147
  ETE 1.448 (0.483, 4.344) 0.509 1.275 (0.389, 4.180) 0.688
  High NLR* 2.682 (1.347, 5.341) 0.005 2.786 (1.358, 5.713) 0.005
CI: confidence interval, ETE: strap muscle or major organ invasion, LNM: lymph node metastasis, NLR: neutrophil- 
to-lymphocyte ratio, OR: odds ratio
*High NLR as a categorical variable.
central or lateral lymph node metastasis). Odds ratios 
(ORs) with 95% confidence intervals (CIs) for predicting 
aggressive PTC features were calculated for all 
variables. The univariate and multivariate Cox propor-
tional hazard regression models were used to identify 
variables that influenced persistence/recurrence. 
Hazard ratios (HRs) estimated from the Cox analysis 
were reported as relative risks with corresponding 
95% CIs. A p value of less than 0.05 was considered 
statistically significant. Statistical analyses were per-
formed with SAS statistical software (SAS system for 
Windows, version 9.2; SAS institute, Cary, NC, USA).
Results
Clinicopathologic Characteristics 
The baseline clinicopathologic characteristics for the 
included patients are shown in Table 1. The mean 
age of the 205 patients at diagnosis was 47 years 
(standard deviation [SD], 13 years; range, 17-80 
years); 175 women (mean age, 47 years; range, 
17-80 years) and 30 men (mean age, 47 years; 
range, 25-66 years). The mean tumor size was 18.9 
mm (SD, 8.4 mm; range, 11-50 mm). Sixty-six pa-
tients (32.2%) had multiple PTCs and 17 patients 
(8.3%) had pathologic extrathyroidal extension (strap 
muscle or major organ invasion). Central and lateral 
LNM were found in 56.1% (115/205) and 22.9% 
(47/205) of all patients, respectively. Five (2.4%) out 
of 205 patients had distant metastasis found at initial 
diagnosis (the lung in 3 patients, lung and bone in one 
patient, and lung, bone and brain in one patient). 
Three patients (1.5%) had cancers in advanced 
stages (stage III-IV). One hundred and seventy-four 
patients (84.9%) underwent radioactive iodine treat-
ment after surgery; 30 mCi was administered in 159 
patients and 50-200 mCi was administered in 190 
patients. Persistent disease was observed in 16 pa-
tients (7.8%), structural recurrence in 10 patients 
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Table 3. Clinicopathologic characteristics according to persistence/recurrence
Variables Persistence/recurrence group (n=22) Disease-free group (n=183) p
Age 50.86±18.68 46.53±12.18 0.3
Gender 0.104
  Female 16 (72.73) 159 (86.89)
  Male 6 (27.27) 24 (13.11)
Mean size 26.41±10.05 17.98±7.76 ＜0.001
Multifocality 7 (31.82) 59 (32.24) 0.968
ETE 0.040
  Intrathyroid 1 (4.5) 53 (29.0)
  Minimal ETE 19 (86.4) 115 (62.8)
  Strap muscle invasion 2 (9.1) 10 (5.5)
  Major organ invasion 0 (0) 5 (2.7)
LNM 19 (86.4) 100 (54.6) 0.005
RAI dose 65.23±73.30 31.48±30.88 0.044
TNM stage ＜0.001
  I 11 (50.0) 161 (88.0)
  II 8 (36.4) 22 (12.0)
  III 0 0
  IV 3 (13.6) 0 (0)
NLR* 2.03 (0.952-14.689) 1.76 (0.677-9.657) 0.134
ETE: extrathyroidal extension, LNM: central or lateral lymph node metastasis, NLR: neutrophil-to-lymphocyte ratio, RAI: 
radioactive iodine, TNM: tumor-node metastasis 
*Median NLR value as a continuous variable, data in parentheses are the range.
(4.9%) and both persistent disease and structural re-
currence in 4 patients (2.0%).
Predicting Factors for Aggressive Features of 
cPTC
The median value of NLR for all patients was 1.78 
and it was defined as the reference value. According 
to the reference value (1.78), 102 patients had a high 
NLR (＞1.78) and 103 patients had a low NLR (≤1.78). 
In the high NLR group, there were significantly more 
males than females (p=0.016). The high NLR group 
also had a significantly higher presence of lateral LNM 
(p=0.004) and significantly higher radioactive iodine 
doses (p=0.006) than the low NLR group. There were 
no significant differences in mean age, tumor size, ex-
trathyroidal extension, central LNM, multifocality, distant 
metastasis, higher TNM stage, and persistence/re-
currence between the high NLR group and the low 
NLR group. 
High NLR was an independent risk factor for lateral 
LNM (Table 2). The OR of high NLR was 2.786 (95% 
CI: 1.358, 5.713; p=0.005) at multivariate analysis. 
High NLR was not associated with extrathyroidal ex-
tension and central LNM at both univariate and multi-
variate analyses. Tumor size was predictor for central 
LNM in PTCs. Tumor size and high NLR were pre-
dictors for lateral LNM in PTCs. 
Predicting Factors for Persistence/Recurrence of 
cPTC
Table 3 compares clinicopathological features of the 
persistence/recurrence group and the disease-free 
group. The median NLR value as a continuous varia-
ble was not significantly different between the persis-
tence/recurrence group and the disease-free group 
(2.03 vs. 1.76, p=0.134). Age at operation and gen-
der were similar between the two groups. The persis-
tence/recurrence group had larger tumors (26.4 vs. 
18.0 mm, p＜0.001) and increased RAI doses 
(p=0.044). LNM (86.4 vs. 54.6%, p=0.005) and higher 
TNM stage (13.6 vs. 0%, p＜0.001) were more com-
mon in the persistence/recurrence group. 
On univariate Cox regression analysis, preoperative 
high NLR was not significantly associated with persis-
tence/recurrence (Table 4). The mean tumor size and 
RAI dose were found to be independent predictors of 
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Table 4. Predictors of persistence/recurrence defined by univariate and multivariate Cox regression analyses
Variables
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Age 1.026 (0.993, 1.060) 0.119
Gender 2.420 (0.946, 6.186) 0.065
Mean size 1.086 (1.047, 1.126) ＜0.001 1.067 (1.028, 1.107) 0.001
RAI dose 1.013 (1.007, 1.020) ＜0.001 1.009 (1.002, 1.0015) 0.007
Multifocality 1.015 (0.414, 2.490) 0.974
ETE 1.16 (0.258, 4.732) 0.892
LNM 5.064 (1.497, 17.137) 0.009 3.262 (0.927, 11.470) 0.065
High NLR* 1.819 (0.763, 4.337) 0.177
CI: confidence interval, ETE: strap muscle or major organ invasion, HR: hazard ratio, LNM: lymph node metastasis, NLR: 
neutrophil-to-lymphocyte ratio, RAI: radioactive iodine
*High NLR as a categorical variable.
persistence/recurrence on multivariate Cox regression 
analysis. 
Discussion
Neutrophils contribute to tumor growth and meta-
stasis by producing various cytokines/chemokines 
and reactive oxygen species (ROS) which cause DNA 
damage and remodel the extracellular matrix leading 
to tissue destruction.6-9) A high neutrophil count has 
been associated with higher mortality in several ad-
vanced or metastatic cancers, such as advanced 
non-small cell lung cancer,19) metastatic renal cell 
carcinoma,20) and metastatic melanoma.21) Lymphocytes 
play a considerable role in cancer immunity by halting 
the growth of cancer. If a patient has a higher con-
centration of tumor–infiltrating lymphocytes, he/she 
shows better prognosis, a phenomenon which was 
first reported for melanoma22) and breast cancer.23) In 
different types of cancer, if a cancer patient has a 
lower peripheral blood lymphocyte count, he or she 
has a poorer chance of survival.24,25) An association 
between high NLR and worse prognostic outcomes 
has been well demonstrated in various non-thyroid 
cancers, including gastric, colorectal, lung, pancreatic, 
hepatocellular, renal cell carcinoma, cholangiocar-
cinoma and breast cancer.11) 
We found that preoperative high NLR was an in-
dependent predictor for lateral LNM in patients with 
conventional PTCs. Extrathyroidal extension and cen-
tral LNM, well known as aggressive PTC features, 
were not associated with a high NLR. Like this study, 
some studies have reported associations between a 
high NLR and lymph node metastasis for various 
malignancies.26,27) In 353 non-small cell lung cancer 
patients, patients with pN1 or pN2 had significantly 
higher NLRs than patients with pN0 and a high NLR 
was an independent predictor of regional nodal 
involvement.26) In 1131 gastric cancer patients, pre-
operative NLR was significantly positively correlated 
with the number of metastatic lymph nodes.27) In a 
meta-analysis studying the prognostic role of NLR in 
other solid tumors, metastatic diseases were asso-
ciated with high NLRs with a higher hazard ratio than 
nonmetastatic diseases (1.80 vs. 1.57, respectively 
and p=0.12).11) It is unclear why preoperative high 
NLR in cPTC patients is associated with lateral LNM, 
while it is not associated with central LNM. Although 
the mechanism is unclear, we propose more careful 
preoperative evaluation for lateral neck lymph nodes 
when a cPTC patient has a high NLR value. 
In this study, the overall persistence/recurrence rate 
was 10.7% and there were no disease-specific 
deaths. A high NLR was not associated with the per-
sistence/recurrence of conventional PTC. Unlike in 
patients with non-thyroid cancers, some studies have 
reported inconsistent results on the prognostic value 
of high NLR in PTC patients.13,28) As noted above, a 
high NLR has been consistently associated with worse 
overall survival and secondary survival (such as can-
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cer-specific, progression-free, disease-free survival) 
in various non-thyroid cancers.11) Lang et al.13) re-
ported that preoperative NLR did not predict dis-
ease-free survival in clinically nodal-negative PTCs. 
Kim et al.28) reported that high NLR was associated 
with poorer 5-year disease-free survival in advanced 
PTC patients (stage III and IV). PTC patients showed 
relatively low NLR levels compared to patients of other 
non-thyroid cancers.11,12) Furthermore, patients with 
PTC had significantly lower NLR levels than patients 
with poorly differentiated or anaplastic thyroid 
cancer.13,15) Many studies have demonstrated that 
PTCs with lymphocytic infiltrates are associated with 
good prognosis and high disease-free survival.29,30) 
Meanwhile, intratumoral lymphocytic infiltration was in-
tensely reduced or absent in poorly differentiated or 
undifferentiated thyroid carcinoma.31) Consequently, 
lymphocytic infiltration in PTC may have protective ef-
fects and the loss of protective effects in poorly differ-
entiated or anaplastic thyroid carcinoma may contrib-
ute to aggressive behavior and poor prognostic 
outcomes.29-31) 
This study has some limitations. First, our study was 
of retrospective design and 43 patients without avail-
able preoperative blood cell counts were excluded. 
Thus, selection bias is inevitable. Second, our in-
stitution selectively performed lateral lymph node dis-
section when a lateral lymph node was proven to be 
metastatic on preoperative US-fine needle aspiration 
or was suspicious for metastasis on preoperative 
imaging or during surgery. Thus, the incidence of/the 
effect of lateral LNM might be underestimated. Third, 
we did not consider reactive inflammatory cervical 
lymphadenopathy, a common cause of high NLR. The 
presence of reactive inflammatory cervical lympha-
denopathy in patients with cPTC increases the like-
lihood of tissue sampling, which may result in selection 
bias. Fourth, the follow-up periods of the included pa-
tients varied from 3 to 10 years. Some patients might 
have not been followed up for a sufficient length of 
time. Despite these limitations, our study has several 
potential strengths. Whereas previous studies covered 
a broad thyroid cancer spectrum from differentiated 
thyroid cancer to anaplastic thyroid carcinoma,12-15) 
our study investigated only conventional PTCs. 
Therefore, our results clarified the clinical significance 
of preoperative NLR on conventional PTCs which 
comprise the majority of thyroid malignancies. 
In conclusion, preoperative high NLR was sig-
nificantly associated with lateral LNM in patients with 
cPTCs, although preoperative high NLR was not sig-
nificantly associated with persistence/recurrence in 
patients with cPTCs.
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